WebThe clonoSEQ ® Assay is a robust, highly-validated tool for identifying and monitoring measurable residual disease (MRD) in lymphoid malignancies. [1] Across a variety of large, multi-center clinical trials, clonoSEQ has generated a wealth of peer-reviewed clinical evidence in disease states including multiple myeloma (MM), B-cell acute ... WebThe clonoSEQ Assay is being utilized for a variety of investigator-sponsored clinical trials in B-cell lymphoid cancers. If you are interested in learning more about use of clonoSEQ in your own trials, contact [email protected]. Contact Us Make an inquiry to learn more about our products. REQUEST INFORMATION Citations
Ordering │ clonoSEQ® MRD for Clinicians
WebSep 11, 2024 · Diagnostic Test: clonoSEQ Assay. Detailed Description: Data show that detection of MRD may be important to guide treatment decisions in ALL, MM, CLL, and … WebApr 13, 2024 · The collaboration will use Adaptive’s clonoSEQ Assay to assess minimal residual disease (MRD) to support the development and commercialisation of Takeda’s … cpo food closet
Technical Summary │ clonoSEQ® MRD for Clinicians
WebThe clonoSEQ® Tracking (MRD) Test uses follow-up samples for the purposes of following the immune receptor sequence(s) identified by the clonoSEQ Clonality (ID) Test. Follow … WebApr 1, 2015 · Adaptive Biotechnologies' clonoSEQ process enables physicians to utilize sequencing-based minimal residual disease (MRD) detection as a clinical decision-making tool for patients with lymphoid... WebDec 8, 2024 · The real-world impact of the use of Adaptive’s clonoSEQ® Assay is exciting for physicians and patients alike. It is the first and only FDA-cleared test that measures MRD in select blood cancers including multiple myeloma, chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (ALL). cpof operators course